Memo Safe Kidney II
Brief description of study
This is a pivotal phase II/III, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of AntiBKV in KTRs (kidney transplant recipients).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting